about
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smallerHow Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast CancerTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.Clinical application of the 70-gene profile: the MINDACT trialAdjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25.Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapyEfficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.Targeted therapies in breast cancer: are heart and vessels also being targeted?Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial.The evolving role of aromatase inhibitors in adjuvant breast cancer therapy.Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available EvidenceAdjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn.Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer : Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be tAnalysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.Trastuzumab (herceptin) for early-stage breast cancer.Molecular targeted therapies in breast cancer: where are we now?Trastuzumab for early breast cancer: current status and future directions.New generation of breast cancer clinical trials implementing molecular profiling.New therapies for ovarian cancer: cytotoxics and molecularly targeted agents.HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.Facts and controversies in the use of trastuzumab in the adjuvant setting.Genomic grade index is associated with response to chemotherapy in patients with breast cancer.Jumping higher: is it still possible? The ALTTO trial challenge.Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer.PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.Development and validation of gene expression profile signatures in early-stage breast cancer.Stemming resistance to HER-2 targeted therapy.Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer.Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer.Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.Dissecting the heterogeneity of triple-negative breast cancer.
P50
Q24641848-2164D854-7DB9-4E68-80C9-3149F1A1E7A2Q26824542-9D30E376-9E05-410C-9419-9232A53980AEQ27824847-BD25B1D8-248D-413B-8D66-2DC0F501E24AQ27851705-ADCFFC67-FBE3-44D1-8FE7-ADB4998AB915Q27853332-ADCA9BEC-E528-468B-893E-9E831D485678Q28267891-3FD16724-B579-421E-83A9-3BAA666142B7Q30758991-3C3A02B2-8432-4DDE-9A97-0EC7804F94DEQ33604264-70BC8245-D30E-4765-BDED-9E91D9C2271EQ33688726-C7EC039A-5D11-4A21-9063-752EFB76B4D9Q34044771-E610D762-3213-4D37-8623-5573F7CDE26CQ34342897-B30B81B6-5FE7-4B83-AA5B-8108547ED061Q35580011-DD907481-8D73-4665-95AD-EF2171546F46Q35947005-CC03B7CC-FC17-47C1-B8F7-A6A705101E50Q36245324-82770EB5-D561-4233-B3CE-2B4A3376EF1CQ36245341-45E47C61-A1DD-43F1-A0B4-B14DF69AAFCBQ36246794-058DB27C-4C29-4632-9BA4-E29C9AD0D966Q36248498-E634A581-78F7-4080-AF67-6DF7661330A5Q36522424-30EA1946-48F5-47BC-8786-D52946FB6977Q36610188-60335937-CD80-4D1D-9CEA-0949E889FF42Q36630435-613EF6EA-D199-450F-9AD4-471EBDB8D3F8Q36826403-7B3F6E5F-A41F-4BBB-B4C7-28F9D66C3EB2Q36837565-1F810674-617E-45B1-B2E0-AEEFB5462141Q36992945-777FDE60-503F-43A6-B1EF-49FCE9F5FE3DQ37094064-EF84DAB8-C4EA-4A64-82E1-F1A11117DB71Q37110610-E6FDCFBD-5B91-4EDE-A61F-33736E1D64B5Q37184721-E601812C-D834-40BB-B93F-FCD12A3F9DC1Q37240710-5A9EDA60-E9AB-476B-8132-3188602F020CQ37263863-B4C6F884-BA40-4C7B-95B6-CB306C177004Q37278382-BC2CE140-3713-4B2E-8A2F-CE2F3BDF68ABQ37338235-E97D2108-C6F2-43E3-9622-40683736F584Q37373983-483B6B1A-45D1-473A-B42B-22AB28E2B9C0Q37380424-416B3985-6896-4CF6-8934-E5B64A12FC6DQ37384844-D22C8962-B51D-486E-B7FE-595904E2F1DBQ37406061-2FAD66EF-9FA5-4598-B499-6FE8FAF46BD4Q37471532-926E788A-EB5A-48D6-921F-EAA599E9EE25Q37547954-4A11811F-BE06-4D00-99A0-7B84058C3DB1Q37649479-68743B29-D30D-4A83-9262-D91FCF91F755Q37651820-469EE30C-9710-4844-865B-A3DFC1A7402BQ37711732-8FB75B4E-8FE2-43DD-9A9F-E55DE0AED0B2Q37997760-FCF6946E-1BE5-4D5C-9566-6663B8CADAB4
P50
description
onderzoeker
@nl
name
Martine Piccart-Gebhart
@ast
Martine Piccart-Gebhart
@en
Martine Piccart-Gebhart
@es
Martine Piccart-Gebhart
@sl
type
label
Martine Piccart-Gebhart
@ast
Martine Piccart-Gebhart
@en
Martine Piccart-Gebhart
@es
Martine Piccart-Gebhart
@sl
altLabel
M J Piccart-Gebhart
@en
M Piccart-Gebhart
@en
M. J. Piccart-Gebhart
@en
M. Piccart-Gebhart
@en
Martine J Piccart-Gebhart
@en
Martine J. Piccart-Gebhart
@en
prefLabel
Martine Piccart-Gebhart
@ast
Martine Piccart-Gebhart
@en
Martine Piccart-Gebhart
@es
Martine Piccart-Gebhart
@sl